Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Income from Continuing Operations: 2013-2025

Historic Income from Continuing Operations for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Income from Continuing Operations rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 144.15%. This contributed to the annual value of -$64.0 million for FY2024, which is 15.94% down from last year.
  • As of Q3 2025, Theravance Biopharma's Income from Continuing Operations stood at $3.6 million, which was down 93.41% from $54.8 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Income from Continuing Operations high stood at $54.8 million for Q2 2025, and its period low was -$79.7 million during Q1 2021.
  • Its 3-year average for Income from Continuing Operations is -$6.8 million, with a median of -$12.7 million in 2024.
  • As far as peak fluctuations go, Theravance Biopharma's Income from Continuing Operations plummeted by 171.45% in 2024, and later skyrocketed by 431.75% in 2025.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Income from Continuing Operations stood at -$57.8 million in 2021, then soared by 75.35% to -$14.2 million in 2022, then skyrocketed by 40.23% to -$8.5 million in 2023, then plummeted by 171.45% to -$23.1 million in 2024, then soared by 128.47% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $54.8 million for Q2 2025, and -$13.5 million during Q1 2025.